Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTOMNR9)

• DTT Name: Somatostatin receptor (SSTR)
• Gene Name: SSTR
• DTT Type: Clinical trial target; [1]
• UniProt ID: NOUNIPROTAC
• TTD ID: T26220

Molecular Interaction Atlas (MIA) of This DTT

9 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
177-Lu-oxodotreotide	DMMZS2T	Neuroendocrine cancer	2B72.1	Phase 3	[2]
177Lu-DOTA-octreotate	DMP5L8S	Melanoma	2C30	Phase 3	[1]
177Lu-DOTATATE	DMT8GVU	Hepatitis C virus infection	1E51.1	Phase 2	[1]
Edotreotide	DMQ08AJ	Acromegaly	5A60.0	Phase 2	[3]
FK-962	DMV0MZ3	Alzheimer disease	8A20	Phase 2	[4]
Somatoprim	DMTVS3A	Acromegaly	5A60.0	Phase 2	[5]
177Lu-labelled DOTA-JR11	DMVZ9XL	Neuroendocrine cancer	2B72.1	Phase 1/2	[6]
212Pb-labelled DOTAMTATE	DMN9MPX	Neuroendocrine cancer	2B72.1	Phase 1	[7]
AlphaMedix	DMBVM1Q	Neuroendocrine cancer	2B72.1	Phase 1	[8]

3 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BIM-23268	DMIZ59O	Acromegaly	5A60.0	Discontinued in Phase 2	[3]
FK-960	DMPD8O2	Cognitive impairment	6D71	Discontinued in Phase 2	[4]
SEGLITIDE	DMXZVPH	Pain	MG30-MG3Z	Discontinued in Phase 2	[9]

1 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ilatreotide	DMPIV1G	Duodenal ulcer	DA63	Investigative	[10]

References

• [1] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
• [2] Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.
• [3] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [4] FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
• [5] DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34.
• [6] Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398.
• [7] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [8] Clinical pipeline report, company report or official report of Orano Med.
• [9] Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899.
• [10] Inhibitory effect of intraduodenal administration of somatostatin analogue SDZ CO 611 on rat pancreatic exocrine secretion. Pancreas. 1993 Jul;8(4):471-5.